First-line brentuximab vedotin plus chemotherapy to improve overall survival in patients with stage III/IV classical Hodgkin lymphoma: An updated analysis of ECHELON-1
Authors
Ansell, S. M.Connors, J. M.
Radford, John A
Kim, W. S.
Gallamini, A.
Ramchandren, R.
Friedberg, J. W.
Advani, R. H.
Hutchings, M.
Evens, A. M.
Smolewski, P.
Savage, K. J.
Bartlett, N. L.
Eom, H. S.
Abramson, J. S.
Dong, C.
Campana, F.
Fenton, K.
Puhlmann, M.
Straus, D. J.
Affiliation
Mayo Clinic, Rochester, MNIssue Date
2022
Metadata
Show full item recordCitation
Ansell SM, Connors JM, Radford JA, Kim WS, Gallamini A, Ramchandren R, et al. First-line brentuximab vedotin plus chemotherapy to improve overall survival in patients with stage III/IV classical Hodgkin lymphoma: An updated analysis of ECHELON-1. Journal of Clinical Oncology. 2022 Jun;40(16). PubMed PMID: WOS:000863680301966.Journal
Journal of Clinical OncologyDOI
10.1200/JCO.2022.40.16_suppl.7503Additional Links
https://dx.doi.org/10.1200/JCO.2022.40.16_suppl.7503Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1200/JCO.2022.40.16_suppl.7503